Oncotype DX Online Ordering Portal Signup

Oncotype DX Online Ordering Portal Signup

Oncotype DX Online Ordering Portal Signup

Oncotype DX Online Ordering Portal Signup

Oncotype DX Online Ordering Portal Signup

Your Information

Practice Information

Add Physicians or Delegates to the Account

NOTE: If you need to submit more than 5 new users, please contact Customer Service.

Oncotype DX AR-V7 Nucleus Detect test

The first and only test to identify patients with metastatic castration resistant prostate cancer who will not respond to AR-targeted therapies. The Oncotype DX AR-V7 Nucleus Detect test identifies patients resistant to androgen-receptor (AR) therapies such as abiraterone and enzalutamide. Learn more about the test→

Confirm Your Information

Submission Information
Practice Information
User Information
AR-V7 Nucleus Detect Interest
Are you interested in ordering the Oncotype DX AR-V7 Nucleus Detect test?

Confirm
 
Add
Remove

Does your practice or institution already have an account?

If you are unsure, please select "No".

Add
Remove

Would you like to add other users to the account?

+Add more users
-Remove user
Add
Remove
Add
Remove

Stay in Touch

Have a specific question? Want to keep up with our latest news? We're here for you.

Contact Us
Making cancer care smarter.®
X

We may use cookies to improve your experience with our website and to provide you with more relevant content based on your interests. To learn more about what information we collect, how we use it, and how to manage cookies, review our Privacy Policy.